Sandostatin (octreotide acetate) — United Healthcare
Malignant bowel obstruction
Initial criteria
- Diagnosis of malignant bowel obstruction
- AND
- Gut function cannot be maintained
Reauthorization criteria
- Documentation of positive clinical response to Sandostatin therapy
Approval duration
12 months